Skip to main content
    L

    Lifecore Biomedical Inc. (LFCR)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $6.44
    +0.02 (+0.31%)

    Market Cap: $243.36M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    48%(19/40)
    Avg Surprise
    -135.40%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Jun 30, 2026
    EPS Consensus$-0.22
    Range$-0.30 - $-0.17
    4 analysts
    EPS Revisions
    2
    0
    7d
    2
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.21-4.7%
    60d ago$-0.220.0%
    30d ago$-0.220.0%
    7d ago$-0.220.0%
    Current$-0.22
    Revenue Consensus
    $32M
    Range$31M - $33M
    5 analysts
    Period ending Sep 30, 2026
    EPS Consensus$-0.31
    Range$-0.33 - $-0.30
    3 analysts
    EPS RevisionsNo revisions (7d)
    0
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.22-42.5%
    60d ago$-0.22-42.5%
    30d ago$-0.30-4.2%
    7d ago$-0.30-4.2%
    Current$-0.31
    Revenue Consensus
    $26M
    Range$25M - $26M
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    May 27EST
    		-$0.07---
    Dec 26EST
    		-$-0.09---
    Sep 26EST
    		-$-0.31---
    Jun 26EST
    		-$-0.22---
    Aug 26
    Reported Aug 31
    		$-0.19$-0.22+14.61%Beat+55.8%
    May 26
    Reported Aug 5
    		$-0.19$-0.17-11.76%Miss-90.0%
    Feb 26
    Reported Mar 16
    		$-0.16$-0.23+30.43%Beat+66.0%
    Nov 25
    Reported Jan 1
    		$0.00N/A+100.00%Beat+100.0%
    Aug 25
    Reported Nov 6
    		$-0.43$-0.30-43.33%Miss-16.2%
    May 25
    Reported Aug 7
    		$-0.10$-0.09-11.11%Miss+41.2%
    Feb 25
    Reported Apr 3
    		$-0.47$-0.15-213.33%Miss-211.9%
    Nov 24
    Reported Jan 2
    		$-0.20$-0.30+33.33%Beat-53.8%
    Aug 24
    Reported Oct 4
    		$-0.37$-0.46+19.57%Beat+69.0%
    May 24
    Reported Aug 26
    		$-0.17$-0.12-41.67%Miss-54.5%
    Feb 24
    Reported May 22
    		$0.42$0.13+223.08%Beat+200.0%
    Nov 23
    Reported Dec 29
    		$-0.13$-0.23+43.48%Beat+38.1%
    Aug 23
    Reported Nov 14
    		$-1.19$-0.23-418.13%Miss-272.4%
    May 23
    Reported Jun 1
    		$-0.11$-0.07-57.14%Miss-1000.0%
    Feb 23
    Reported Mar 16
    		$-0.42$-0.11-281.82%Miss-425.0%
    Nov 22
    Reported Feb 27
    		$-0.21$-0.04-425.00%Miss+4.5%
    Aug 22
    Reported Oct 6
    		$-0.32$-0.13-146.15%Miss-39.1%
    May 22
    Reported Aug 10
    		$-0.01$-0.01+0.00%Beat-114.3%
    Feb 22
    Reported Apr 5
    		$-0.08$-0.03-166.67%Miss+57.9%
    Nov 21
    Reported Jan 5
    		$-0.22$-0.09-144.44%Miss-1200.0%
    Aug 21
    Reported Sep 29
    		$-0.23$-0.12-91.67%Miss+39.5%
    May 21
    Reported Jul 28
    		$0.07$-0.01+800.00%Beat+40.0%
    Feb 21
    Reported Apr 7
    		$-0.19$0.04-575.00%Miss+51.3%
    Nov 20
    Reported Jan 6
    		$0.02$0.03-33.33%Miss+112.5%
    Aug 20
    Reported Oct 6
    		$-0.38$-0.13-192.31%Miss-137.5%
    May 20
    Reported Aug 11
    		$0.05$0.03+66.67%Beat+600.0%
    Feb 20
    Reported Mar 31
    		$-0.39$-0.01-3800.00%Miss-1075.0%
    Nov 19
    Reported Jan 2
    		$-0.16$-0.06-166.67%Miss-700.0%
    Aug 19
    Reported Oct 1
    		$-0.16$-0.16+0.00%Beat-1700.0%
    May 19
    Reported Jul 30
    		$-0.01$-0.02+50.00%Beat-104.2%
    Feb 19
    Reported Apr 3
    		$0.04$0.05-20.00%Miss-55.6%
    Nov 18
    Reported Jan 3
    		$-0.02$-0.02+0.00%Beat-200.0%
    Aug 18
    Reported Oct 2
    		$0.01N/A-83.33%Miss-87.5%
    May 18
    Reported Jul 31
    		$0.24$0.22+9.09%Beat+166.7%
    Feb 18
    Reported Apr 3
    		$0.09$0.09+0.00%Beat-50.0%
    Nov 17
    Reported Jan 3
    		$0.02$0.01+100.00%Beat-60.0%
    Aug 17
    Reported Sep 26
    		$0.08$0.06+33.33%Beat-
    May 17
    Reported Jul 25
    		$0.09$0.09+0.00%Beat-
    Feb 17
    Reported Apr 4
    		$0.18$0.18+0.00%Beat-
    Nov 16
    Reported Jan 4
    		$0.05$0.06-16.67%Miss-

    Key Metrics

    Valuation
    P/E Ratio-6.64EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-23.80%Operating Margin7.51%
    ROE-76.40%ROICN/A
    Financial Health
    Debt/Equity-4.52xInterest CoverageN/A
    Current Ratio3.87xQuick Ratio2.69x
    Trading Statistics
    Beta0.98Avg Volume641.32K
    52-Week High$8.9852-Week Low$3.63

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$6.46
    SMA 20$5.85
    SMA 50$5.04
    SMA 200$5.59
    EMA 10$6.32
    EMA 20$5.95
    EMA 50$5.36
    EMA 200$5.52

    MACD

    Line: 0.49Signal: 0.49Hist: -0.00

    ADX

    ADX: 39.0+DI: 43.3-DI: 13.7

    Aroon & PSAR

    Aroon Up48.0
    Aroon DownN/A
    PSAR$5.52

    Bollinger Bands

    Upper Band$7.83
    Lower Band$3.88
    %B Position6754%(Upper)
    Band Width0.65

    RSI (14-Day)

    Overbought
    74.3

    Momentum Oscillators

    Stoch %K66.1
    Stoch %D83.1
    Williams %R-83.7
    ROC (10d)-1.4%
    Momentum-0.09
    CCI (20d)44.7
    MFI (14d)51.1

    Volatility Measures

    ATR (14d)$0.18(2.8%)
    StdDev (20d)0.99
    Hist Vol198.0%(High)

    Volume Flow

    VWAP$6.45
    OBV-4.0M
    AD Line-6.8M
    CMF (20d)-0.226

    Volume Metrics

    Avg Vol (20d)693.5K
    Vol Ratio0.3x(Low)
    VWMA (20d)$6.36

    Pivot Points

    R3$6.48
    R2$6.46
    R1$6.44
    Pivot Point$6.42
    S1$6.40
    S2$6.38
    S3$6.36

    Advanced Oscillators

    TSI48.24
    Ultimate Osc54.9
    KST440.26

    Financial Data

    QuarterJun 2026Mar 2026Feb 2026Nov 2025Aug 2025May 2025Feb 2025Nov 2024Aug 2024May 2024Feb 2024Nov 2023
    Total Revenue$34.17M$23.19M$23.19M$34.17M$23.19M$36.44M$35.15M$32.56M$24.70M$37.88M$35.70M$30.15M
    Cost of Revenue$22.09M$18.73M$18.73M$22.09M$18.73M$22.46M$25.31M$21.48M$19.32M$20.61M$23.81M$20.19M
    Gross Profit$12.07M$4.46M$4.46M$12.07M$4.46M$13.98M$9.85M$11.08M$5.39M$17.27M$11.89M$9.96M
    Operating Expenses$9.51M$9.13M$9.13M$9.51M$9.13M$8.65M$18.87M$13.04M$16.97M$15.12M$12.79M$11.44M
    R&D$1.54M$1.22M$1.22M$1.54M$1.22M$2.10M$2.04M$1.92M$2.19M$2.16M$2.17M$2.10M
    SG&A$7.97M$7.92M$7.92M$7.97M$7.92M$8.98M$9.98M$11.12M$14.79M$12.08M$9.85M$9.34M
    Operating Income$2.57M$-4,672,000$-4,672,000$2.57M$-4,672,000$5.33M$-9,029,000$-1,959,000$-11,584,000$2.15M$-895,000$-1,483,000
    Interest Income$144,000$128,000$128,000$144,000$128,000$206,000$108,000$206,000$15,000$0$-4,289,000$0
    Interest Expense$7.75M$7.35M$7.35M$7.75M$7.35M$5.73M$5.59M$5.46M$5.38M$9.29M$0$4.07M
    Income Before Tax$-6,133,000$-14,937,000$-14,937,000$-6,133,000$-14,937,000$-1,114,000$-14,777,000$-6,528,000$-16,255,000$-7,143,000$15.00M$14.18M
    Income Tax Expense$23,000$43,000$43,000$23,000$43,000$33,000$-8,000$43,000$-25,000$-57,000$217,000$-65,000
    Net Income$-6,156,000$-14,980,000$-14,980,000$-6,156,000$-14,980,000$-1,147,000$-14,769,000$-6,571,000$-16,230,000$-7,083,000$15.63M$14.22M
    EBITDA$3.99M$-5,407,000$-5,279,000$3.99M$-5,407,000$6.40M$-7,220,000$6.40M$-8,894,000$661,000$21.30M$20.02M
    EBIT$1.47M$-7,717,000$-7,589,000$1.47M$-7,717,000$4.41M$-9,296,000$4.41M$-10,887,000$-1,353,000$19.29M$18.25M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about LFCR

    News

    Lifecore Biomedical to Participate at Upcoming Industry Conferences

    Lifecore Biomedical, a fully integrated injectables CDMO, announced its participation in three upcoming industry events: CDMO Live Americas, Partnership Opportunities in Drug Development (PODD)...

    GlobeNewswire•10/8/26•Somewhat-Bullish

    Lifecore Biomedical Q2 2026 Earnings Call Transcript

    Lifecore Biomedical reported a decrease in Q2 2026 revenues to $34.2 million, down 6.2% from the prior year, and a net loss of $6.2 million. Despite this, the company reaffirmed its 2026 guidance...

    Benzinga•10/8/26•Somewhat-Bullish

    At three Boston conferences, Lifecore leaders will meet prospective customers.

    Lifecore Biomedical (LFCR) announced its participation in three upcoming industry conferences in Boston: CDMO Live Americas, PODD...

    Stock Titan•10/7/26•Somewhat-Bullish

    Lifecore Biomedical (LFCR) was downgraded to a Hold Rating at William Blair

    William Blair analyst Jared Haase downgraded Lifecore Biomedical (LFCR) to a Hold rating on October 3. Despite this, the company reported increased quarterly revenue of $34.17 million...

    The Globe and Mail•10/7/26•Bearish

    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RXO Inc. (NYSE – RXO), PTC Inc. (Nasdaq – PTC), Lifecore Biomedical, Inc. (Nasdaq – LFCR), WaFd, Inc. (Nasdaq – WAFD)

    Brodsky & Smith is investigating potential breaches of fiduciary duties by the Boards of Directors of RXO Inc., PTC Inc., Lifecore Biomedical, Inc., and WaFd...

    Supply Chain Digital•10/5/26•Neutral

    LFCR Valuation and Fair Value

    P/E
    -6.6x
    Forward P/E
    8.7x
    PEG
    2.7x
    P/B
    -7.1x
    See GNG's fair value

    LFCR Profitability: Margins, ROIC and FCF

    Operating margin
    7.5%
    Net margin
    -23.8%
    ROE
    -76.4%

    LFCR Competitors

    CompanyTicker
    SAB Biotherapeutics IncSABS
    X4 Pharmaceuticals IncXFOR
    Bicycle Therapeutics LtdBCYC
    Rocket Pharmaceuticals IncRCKT
    So-Young International IncSY
    Profound Medical CorpPROF
    BioAge Labs, IncBIOA
    TriSalus Life Sciences Inc.TLSI

    Sector: Healthcare

    LFCR Analyst Ratings

    Consensus
    Hold
    Analysts
    4
    Strong Buy
    0
    Buy
    0
    Hold
    4
    Sell
    0
    Strong Sell
    0

    LFCR Bull Case vs Bear Case

    Bear case

    • LFCR has a -23.8% net profit margin.
    • LFCR's quarterly revenue changed -3.8% year over year.

    LFCR Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -12.6%
    EPS estimate (fiscal period ending Jun 30, 2026)
    $-0.22
    Estimate revisions (30 days, fiscal period ending Jun 30, 2026)
    2 up, 1 down

    Frequently Asked Questions About LFCR

    Does LFCR pay dividends?

    Lifecore Biomedical Inc. (LFCR) does not currently pay a regular dividend.

    What is LFCR's market cap?

    Lifecore Biomedical Inc. (LFCR) has a market capitalization of $243.36M with a current stock price of $6.44.

    Related stocks

    Sector: Healthcare

    All stocks starting with L

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In